Moise Khayrallah, Ph.D.

CEO, Emergo Therapeutics

Dr. Khayrallah has been involved in pharmaceutical drug development for 30 years in executive as well as research and development positions. He acquired his experience in diverse pharmaceutical environments including large pharmaceutical, contract research, and biotechnology companies.
Emergo Therapeutics is his fifth startup biopharmaceutical company in the last 11 years. He is also currently Chairman of the Board of Target Pharma Solutions, a clinical data company that works with pharmaceutical partners and the Food and Drug Administration to better understand the natural history of diseases, including treatment outcomes in the real-world setting.
Prior to these current positions, Dr. Khayrallah co-founded and led QuatroBio, LLC; Aerial BioPharma, LLC; Neuronex Inc.; Addrenex Pharmaceuticals, Inc.; and Alius Pharma, LLC. He also has held positions at Cytran, Inc., Lineberry Research Associates (later Constella Group and SRI International) in RTP, NC; Burroughs Wellcome Co. and later Glaxo Wellcome. He holds a Ph.D. degree in psychology from the University of North Carolina at Chapel Hill and a Bachelor’s degree in psychology from the American University of Beirut. Dr. Khayrallah is also actively involved with the entrepreneurial and social networks in the Research Triangle area of North Carolina.

Bobby Helmedag, MBA

Managing Director, Rex Health Ventures

Bobby oversees the day-to-day operations of the fund. Bobby serves as the Rex Health Ventures Board representative for Midnight Pharma, Target PharmaSolutions, and Phynd Technologies as well as having Board observer roles with Aerial BioPharma and Awarepoint. He joined UNC REX Healthcare in 2010. Previously, Bobby worked for BlueCross BlueShield of Tennessee in the Corporate Development group. He has also held positions with an investor group in Columbia, S.C., Citigroup, and KPMG.
Bobby received his International MBA from the Moore School of Business at the University of South Carolina, studying in Germany, England, and Australia. He received his undergraduate degree in finance from the University of Notre Dame.

Meg Powell, MBA, Pharm.D.

Board Chair and Co-Founder, TARGET PharmaSolutions

Dr. Powell has over 15 years of experience in the pharmaceutical industry including assignments at McKinsey, Eli Lillypost-patentin-depth, and GlaxoSmithKline. Currently she is serving as Board Chair and is the Co-Founder of TARGET PharmaSolutions.
She has worked with multiple start-up companies while at Medgility, a consulting firm focused on Strategy and Business Development of Emerging Companies. These include Qura Therapeutics, KemPharm, Inc, and most notably, Aerial Biopharma where she was the Interim VP of Corporate Development and was instrumental in the sale of ADX-N05 to Jazz Pharmaceuticals.
Prior to her work at Medgility, Dr. Powell was Vice President of the US Transformation Office at GlaxoSmithKline. She has in depth experience in sales and marketing for US and Global development programs at all stages – from Phase 1 to post patent expiry.
Dr. Powell received her Doctorate of Pharmacy degree from the University of North Carolina- Chapel Hill where she was a Hollingsworth Scholar. She also received a Master’s of Business Administration from Stanford University.

Jack Bailey, MBA

President, US Pharmaceuticals at GlaxoSmithKline

Jack Bailey oversees GSK’s pharmaceuticals and vaccines businesses in the US and Puerto Rico.  In this role, Jack draws upon 25 years of industry experience and a successful track record of leading organizations through change, delivering strong business performance, and maintaining a focus on patient access and affordability. Jack joined GSK in 2009 as a senior vice president.
Prior to joining GSK, Jack had a successful 18-year career with Eli Lilly, where he served in a variety of commercial leadership roles including senior vice president of the account-based markets division, general manager for Eli Lilly South Africa, and area director for the sub-Saharan region.
Jack holds a Master of Business Administration from the University of North Carolina, Kenan Flagler School of Business. He is actively involved in the community and the healthcare sector in the state, and has served on the boards of the North Carolina Biotechnology Center, the North Carolina Healthcare Quality Alliance, and the North Carolina Chamber of Commerce. Jack serves on the board of the Pharmaceutical Research and Manufacturers of America (PhRMA) and is currently a member of the Health Policy and Management Executive Council at the Harvard T.H. Chan School of Public Health.